Leiden, March 17, 2010 – Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, announces the appointment of Berndt Modig as Chief Financial Officer (CFO).
Berndt Modig (51) brings more than 20 years of international experience in company finance to Prosensa. In his previous position as CFO of Jerini AG, a German drug discovery and development company, he managed several financing operations, including the company’s IPO on the Frankfurt stock exchange. He also co-ordinated the acquisition of Jerini by Shire. Before this, Berndt was CFO at Surplex AG and Finance Director Europe of Hayward Industrial Products GmbH, a European subsidiary of Hayward Industries Inc. As co-founder and partner in Agra Industria Sprl and investment manager at IMM GmbH he gained experience in private equity. He started his career at Price Waterhouse in the US where he held several positions in the Financial Services Group. Berndt has a Bachelor degree in Business Administration, Economics and German from the University of Lund, Sweden, an MBA from INSEAD, France and is a Certified Public Accountant.
“We continue to build a strong multinational management team at Prosensa to support our growth strategy. With his distinguished track record of successfully building value in the private and public arena, Berndt has the right expertise to help us execute our business objective of becoming a leading provider of therapeutic solutions for rare neuromuscular disorders” said Hans Schikan, CEO of Prosensa.
Commenting on his new appointment, Berndt Modig said: “Prosensa is an exciting biotechnology company with great potential. I look forward to the opportunity of working with the team to create significant value for its shareholders as the company develops into a leading biopharmaceutical company.”
